Table 2.
Patient demographic and clinical characteristics in the 250-patient subset
| All Patients (N = 250) |
Apalutamide (N = 125) |
Enzalutamide (N = 125) |
|
|---|---|---|---|
| Age at most recent visit, years | |||
| Mean (SD) | 70.84 (7.84) | 70.41 (8.21) | 71.28 (7.45) |
| Median (Q1-Q3) | 70.0 (66.0–76.0) | 70.0 (66.0–76.0) | 71.0 (66.0–77.0) |
| Race, N (%) | |||
| White or Caucasian | 180 (72.0) | 91 (72.8) | 89 (71.2) |
| Black or African/Caribbean origin | 65 (26.0) | 31 (24.8) | 34 (27.2) |
| Asian | 2 (0.8) | 0 (0.0) | 2 (1.6) |
| American Indian/Alaska Native | 1 (0.4) | 1 (0.8) | 0 (0.0) |
| Unknown | 2 (0.8) | 2 (1.6) | 0 (0.0) |
| Healthcare coverage at most recent visit, N (%) | |||
| Medicaid | 28 (11.2) | 15 (12.0) | 13 (10.4) |
| Medicare | 186 (74.4) | 92 (73.6) | 94 (75.2) |
| Medigap | 5 (2.0) | 3 (2.4) | 2 (1.6) |
| Private | 24 (9.6) | 10 (8.0) | 14 (11.2) |
| Traditional fee-for-service | 5 (2.0) | 3 (2.4) | 2 (1.6) |
| Health maintenance organization | 9 (3.6) | 2 (1.6) | 7 (5.6) |
| Preferred provider organization | 27 (10.8) | 18 (14.4) | 9 (7.2) |
| Veterans Affairs | 2 (0.8) | 0 (0.0) | 2 (1.6) |
| Body mass index at most recent visit | |||
| Mean (SD) | 27.47 (3.90) | 27.46 (3.76) | 27.47 (4.05) |
| Median (Q1-Q3) | 26.8 (25.0–28.9) | 27.0 (25.3–28.8) | 26.8 (24.8–29.0) |
| Charlson Comorbidity Index, N (%)a | |||
| 0 | 162 (64.8) | 85 (68.0) | 77 (61.6) |
| 1 | 60 (24.0) | 27 (21.6) | 33 (26.4) |
| 2+ | 28 (11.2) | 13 (10.4) | 15 (12.0) |
| ECOG score at nmCRPC diagnosis, N (%) | |||
| 0 | 83 (33.2) | 34 (27.2) | 49 (39.2) |
| 1 | 132 (52.8) | 71 (56.8) | 61 (48.8) |
| 2 | 25 (10.0) | 11 (8.8) | 14 (11.2) |
| 3+ | 2 (0.8) | 2 (1.6) | 0 (0.0) |
| Unknown | 8 (3.2) | 7 (5.6) | 1 (0.8) |
| Gleason score at nmCRPC diagnosis, N (%) | |||
| 2 to 6 | 28 (11.2) | 14 (11.2) | 14 (11.2) |
| 7 | 87 (34.8) | 44 (35.2) | 43 (34.4) |
| 8 to 10 | 94 (37.6) | 47 (37.6) | 47 (37.6) |
| Unknown | 41 (16.4) | 20 (16.0) | 21 (16.8) |
| PSA at nmCRPC diagnosis (ng/mL) | |||
| N | 241 | 118 | 123 |
| Mean (SD) | 23.21 (44.15) | 20.99 (24.91) | 25.35 (56.84) |
| Median (Q1-Q3) | 12.0 (6.7–26.0) | 13.0 (7.0–28.0) | 11.0 (6.5–22.4) |
Abbreviations: ECOG Eastern Cooperative Oncology Group; Q1-Q3, Range between the first quartile (Q1) and third quartile (Q3); nmCRPC non-metastatic castrate-resistant prostate cancer; PSA Prostate specific antigen; SD, Standard deviation
aCharlson Comorbidity Index was calculated using patient comorbidities present from nmCRPC diagnosis through the end of the study period